Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 5/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | SDCBP | O00560 | 1/20 | 0.31 |
| ▸ | SDC2 | P34741 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045397 | 1.00 | NR3C1 (0.38) | NR3C1MGLLMEN1KMT2AHTT | |
| SCHEMBL23071797 | 1.00 | NR3C1 (0.38) | NR3C1MGLLMEN1KMT2AHTT | |
| SCHEMBL23680476 | 0.94 | NR3C1 (0.38) | NR3C1MGLLMEN1KMT2AHTT | |
| SCHEMBL31045379 | 0.92 | NR3C1 (0.36) | NR3C1MGLLMEN1KMT2AHTT | |
| SCHEMBL31045253 | 0.92 | NR3C1 (0.36) | NR3C1MGLLMEN1KMT2AHTT | |
| SCHEMBL23846023 | 0.92 | NR3C1 (0.38) | NR3C1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL24898123 | 0.92 | NR3C1 (0.38) | NR3C1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL23961616 | 0.92 | NR3C1 (0.38) | NR3C1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL23432943 | 0.90 | NR3C1 (0.35) | NR3C1MGLLMEN1KMT2AHTT | |
| SCHEMBL23071942 | 0.90 | NR3C1 (0.41) | NR3C1MEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182569-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | NR3C1 2419/4885MGLL 3034/4885MEN1 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.